A Reliable Research Partner in Life Science and Medicine

Recombinant Human VEGF165 protein (His Tag)

Catalog Number: PDMH100127

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description

Species Human

Source HEK293 Cells-derived Human VEGF165 protein Met1-Arg191, with an C-terminal His

Calculated MW20.9 kDaObserved MW22 kDaAccessionP15692

Bio-activity Not validated for activity

Properties

Purity > 95% as determined by reducing SDS-PAGE.

Endotoxin < 1.0 EU/mg of the protein as determined by the LAL method

Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80

°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.


ShippingThis product is provided as lyophilized powder which is shipped with ice packs.FormulationLyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5%

Mannitol

Reconstitution It is recommended that sterile water be added to the vial to prepare a stock solution of

0.5 mg/mL. Concentration is measured by UV-Vis.

Data



> 95 % as determined by reducing SDS-PAGE.

Background

Elabscience®

Elabscience Biotechnology Co., Ltd.

A Reliable Research Partner in Life Science and Medicine

Human VEGF121, also known as Vascular endothelial growth factor A, VEGFA, Vascular permeability factor, VPF and VEGF, is a homodimeric, heparin-binding glycoprotein which belongs to the platelet-derived growth factor (PDGF)/ vascular endothelial growth factor (VEGF) family. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis, permeabilization of blood vessels and endothelial cell growth, increasing microvascular permeability, promoting cell migration and inhibiting apoptosis. Alternatively spliced transcript variants of VEGF-A encod either secreted or cell-associated isoforms. The lymphangiogenesis may be promoted by upregulation of VEGF121, which may in turn act in part via induction of VEGF-C. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.